No significant differences were reported over the 6-month study period for the 3 groups. All of these measurements (with the exception of height) were taken again at 1, 3, and 6 months.Ī total of 46 patients completed the study. Levels of serum creatinine, hemoglobin, alanine aminotransferase, HbA1c, serum total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, and plasma chromium were also determined. Patients were weighed, their height was measured, and their blood pressure was taken. The participants took 1 supplement tablet with breakfast and another one with dinner.Īt study onset, the duration of diabetes, diabetes treatments, other medication use, and insulin requirements were recorded. The supplements used in the study were made with chromium picolinate containing 12% chro?mium. No alterations were made in cholesterol-reducing, antihypertensive, or oral hypoglycemic regimens during the 6-month study period. The patients were asked not to make any changes to their diet or their insulin dosages. The primary end point was a change in HbA1c. Patients were randomized to 1 of 3 groups: 250 ?g chromium picolinate twice daily (n = 17), 500 ?g chromium picolinate twice daily (n = 17), or placebo (n = 19). All had a body mass index >25 kg/m2 (mean, 34 ? 5.2). This theory stems from the fact that this essential trace mineral has been shown to aid glucose metabolism, and its deficiency is known to lead to glucose intolerance and insulin resistance.Ī 6-month double-blind study that was recently published in Diabetes Care (2006 29:521-525) sought to determine the effects of chromium supplementation on glycemic control in a group of 53 patients (aged 8% and required >50 units per day of insulin. It has been speculated that chromium supplementation might improve insulin sensitivity in patients with type 2 diabetes.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |